Brief: DBP completes pre-clinical development of liver cancer drug candidate
19/04/2017 13:07
April 19 - DOUBLE BOND PHARMACEUTICAL INTERNATIONAL AB
(PUBL) DBPHAB.ST :
* ANNOUNCED ON TUESDAY THAT PRE-CLINICAL TOXICOLOGICAL
DEVELOPMENT OF SA-033 IS NOW COMPLETED
* SA-033 IS DRUG CANDIDATE AGAINST CANCERS IN LIVER
* SA-033 IS NOVEL SELF-NAVIGATING FORMULATION BASED ON
CANCER DRUG DOXORUBICIN
* RESULTS SHOW DAMAGE TO LIVER, KIDNEYS AND IMMUNE SYSTEM
CAUSED BY DOXORUBICIN IN SA-033 ARE MUCH LESS PRONOUNCED
COMPARED TO ORDINARY DOXORUBICIN FORM
Source text: http://bit.ly/2pfTM45
Further company coverage: DBPHab.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University